Also, the DC manufacturing process is different in DIRECT currently, in that it employs Tangential Flow Filtration (TFF), which according to the patent news release results in more potent DCs.
From the Sept 10, 2013 press release:
"Most significantly, the dendritic cells produced through this next generation system, are manufactured using procedures which are more closely related to what one finds in nature. The result is increased potency of the dendritic cells (which are the active agent in the DCVax products)."
My understanding it that the increase in potency is 10X, based on what I read somewhere else. This could also explain why DIRECT is showing such strong efficacy. Also, it would be a potential enhancement to the current L process at some point. I would guess they can't change the manufacturing process in the middle of the Phase III trial.